{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:50:58Z","timestamp":1791255058769,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"DOI":"10.1007\/s41030-026-00387-6","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:53:15Z","timestamp":1790333595000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced Pulmonary Drug Delivery Systems: A Narrative Review"],"prefix":"10.1007","author":[{"given":"Dil","family":"Afrose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melika","family":"Valizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailesh B.","family":"Kolekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mano J.","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandr","family":"Ceasovschih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Corlateanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeesh","family":"Sivapalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"387_CR1","unstructured":"Department of Data and Analytics (DNA) Analytics and Delivery for Impact (DDI) WHO Geneva D of D WHO methods and data sources for country-level causes of death 2000\u20132021. 55."},{"key":"387_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17050539","volume":"17","author":"M Govender","year":"2025","unstructured":"Govender M, Choonara YE. Drug delivery systems for respiratory diseases: insights into the therapeutic innovations for pulmonary administration. Pharmaceutics (Basel). 2025;17:539.","journal-title":"Pharmaceutics (Basel)"},{"key":"387_CR3","doi-asserted-by":"publisher","first-page":"e68639","DOI":"10.7759\/cureus.68639","volume":"16","author":"PK Subramani","year":"2024","unstructured":"Subramani PK, Remya PN, Narayanasamy D. The role of pulmonary drug delivery in modern therapeutics: an overview. Cureus. 2024;16:e68639. https:\/\/doi.org\/10.7759\/cureus.68639.","journal-title":"Cureus"},{"key":"387_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/jgf2.241","volume":"20","author":"S Okauchi","year":"2019","unstructured":"Okauchi S, Kinoshita K, Sato S, et al. Rinsing of oropharynx and storage place of respiratory medicine inhaler: a cross-sectional audit. J Gen Fam Med. 2019;20:101\u20136. https:\/\/doi.org\/10.1002\/jgf2.241.","journal-title":"J Gen Fam Med"},{"key":"387_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1590\/s1806-37132015000000035","volume":"41","author":"JG Maccari","year":"2015","unstructured":"Maccari JG, Teixeira C, Gazzana MB, et al. Inhalation therapy in mechanical ventilation. J Bras Pneumol. 2015;41:467\u201372. https:\/\/doi.org\/10.1590\/s1806-37132015000000035.","journal-title":"J Bras Pneumol"},{"key":"387_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2174\/1874306401408010074","volume":"8","author":"A Vr","year":"2014","unstructured":"Vr A. Inhalational steroids and iatrogenic Cushing\u2019s syndrome. Open Respir Med J. 2014;8:74\u201384. https:\/\/doi.org\/10.2174\/1874306401408010074.","journal-title":"Open Respir Med J"},{"key":"387_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2165\/00002018-199207010-00007","volume":"7","author":"BJ Lipworth","year":"1992","unstructured":"Lipworth BJ. Risks versus benefits of inhaled beta 2-agonists in the management of asthma. Drug Saf. 1992;7:54\u201370. https:\/\/doi.org\/10.2165\/00002018-199207010-00007.","journal-title":"Drug Saf"},{"key":"387_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s43088-025-00646-6","volume":"14","author":"A Gholap","year":"2025","unstructured":"Gholap A, Pardeshi S, Giram P, et al. Breathing new life nanomedicines for pulmonary drug delivery: targeting approaches, experimental models, and regulatory aspects. Beni Suef Univ J Basic Appl Sci. 2025;14:65. https:\/\/doi.org\/10.1186\/s43088-025-00646-6.","journal-title":"Beni Suef Univ J Basic Appl Sci"},{"key":"387_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4103\/0970-2113.92361","volume":"29","author":"JS Patil","year":"2012","unstructured":"Patil JS, Sarasija S. Pulmonary drug delivery strategies: a concise, systematic review. Lung India. 2012;29:44\u20139. https:\/\/doi.org\/10.4103\/0970-2113.92361.","journal-title":"Lung India"},{"key":"387_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1089\/jamp.2020.29029.cd","volume":"33","author":"C Darquenne","year":"2020","unstructured":"Darquenne C. Deposition mechanisms. J Aerosol Med Pulm Drug Deliv. 2020;33:181\u20135. https:\/\/doi.org\/10.1089\/jamp.2020.29029.cd.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"387_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1089\/jamp.2011.0916","volume":"25","author":"C Darquenne","year":"2012","unstructured":"Darquenne C. Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv. 2012;25:140\u20137. https:\/\/doi.org\/10.1089\/jamp.2011.0916.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"387_CR12","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1208\/s12249-014-0092-0","volume":"15","author":"YS Cheng","year":"2014","unstructured":"Cheng YS. Mechanisms of pharmaceutical aerosol deposition in the respiratory tract. AAPS PharmSciTech. 2014;15:630\u201340. https:\/\/doi.org\/10.1208\/s12249-014-0092-0.","journal-title":"AAPS PharmSciTech"},{"key":"387_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1089\/jamp.2021.29036.csk","volume":"34","author":"CS Kim","year":"2021","unstructured":"Kim CS. Physiological factors affecting lung deposition. J Aerosol Med Pulm Drug Deliv. 2021;34:147\u201354. https:\/\/doi.org\/10.1089\/jamp.2021.29036.csk.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"387_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s13346-022-01251-1","volume":"13","author":"S Alipour","year":"2023","unstructured":"Alipour S, Mahmoudi L, Ahmadi F. Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19. Drug Deliv Transl Res. 2023;13:705\u201315. https:\/\/doi.org\/10.1007\/s13346-022-01251-1.","journal-title":"Drug Deliv Transl Res"},{"key":"387_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010031","author":"B Chaurasiya","year":"2020","unstructured":"Chaurasiya B, Zhao YY. Dry powder for pulmonary delivery: a comprehensive review. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics13010031.","journal-title":"Pharmaceutics"},{"key":"387_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-24437-2","volume":"15","author":"M \u015awi\u0105tkowska-Bury","year":"2025","unstructured":"\u015awi\u0105tkowska-Bury M, Zawadzka-Krajewska A, Kulus M, et al. Inhaled anti-asthmatic therapy and tooth wear in children and adolescents: a case-control study. Sci Rep. 2025;15:40489. https:\/\/doi.org\/10.1038\/s41598-025-24437-2.","journal-title":"Sci Rep"},{"key":"387_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.18773\/austprescr.2024.046","volume":"47","author":"D Rigby","year":"2024","unstructured":"Rigby D. Inhaler device selection for people with asthma or chronic obstructive pulmonary disease. Aust Prescr. 2024;47:140\u20137. https:\/\/doi.org\/10.18773\/austprescr.2024.046.","journal-title":"Aust Prescr"},{"key":"387_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.rmed.2017.01.006","volume":"124","author":"P Rogliani","year":"2017","unstructured":"Rogliani P, Calzetta L, Coppola A, et al. Optimizing drug delivery in COPD: the role of inhaler devices. Respir Med. 2017;124:6\u201314. https:\/\/doi.org\/10.1016\/j.rmed.2017.01.006.","journal-title":"Respir Med"},{"key":"387_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s43168-025-00461-8","volume":"19","author":"S Muruganantham","year":"2025","unstructured":"Muruganantham S, Ramesh SL. Soft mist, dry powder, and smart inhalers: comparative technologies and clinical impact on asthma and COPD management. Egypt J Bronchol. 2025;19:109. https:\/\/doi.org\/10.1186\/s43168-025-00461-8.","journal-title":"Egypt J Bronchol"},{"key":"387_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14112495","author":"AR Mohan","year":"2022","unstructured":"Mohan AR, Wang Q, Dhapare S, et al. Advancements in the design and development of dry powder inhalers and potential implications for generic development. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14112495.","journal-title":"Pharmaceutics"},{"key":"387_CR21","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2147\/copd.S297980","volume":"16","author":"A Baloira","year":"2021","unstructured":"Baloira A, Abad A, Fuster A, et al. Lung deposition and inspiratory flow rate in patients with chronic obstructive pulmonary disease using different inhalation devices: a systematic literature review and expert opinion. Int J Chron Obstruct Pulmon Dis. 2021;16:1021\u201333. https:\/\/doi.org\/10.2147\/copd.S297980.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"387_CR22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40199-024-00520-3","volume":"32","author":"N Islam","year":"2024","unstructured":"Islam N, Suwandecha T, Srichana T. Dry powder inhaler design and particle technology in enhancing pulmonary drug deposition: challenges and future strategies. Daru. 2024;32:761\u201379. https:\/\/doi.org\/10.1007\/s40199-024-00520-3.","journal-title":"Daru"},{"key":"387_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2732017","author":"JM Borghardt","year":"2018","unstructured":"Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Can Respir J. 2018. https:\/\/doi.org\/10.1155\/2018\/2732017.","journal-title":"Can Respir J"},{"key":"387_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/8755122518788809","volume":"34","author":"CM Ajimura","year":"2018","unstructured":"Ajimura CM, Jagan N, Morrow LE, Malesker MA. Drug interactions with oral inhaled medications. J Pharm Technol. 2018;34:273\u201380. https:\/\/doi.org\/10.1177\/8755122518788809.","journal-title":"J Pharm Technol"},{"key":"387_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12111025","author":"W Liang","year":"2020","unstructured":"Liang W, Pan HW, Vllasaliu D, Lam JKW. Pulmonary delivery of biological drugs. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12111025.","journal-title":"Pharmaceutics"},{"key":"387_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17040470","author":"S Nana","year":"2025","unstructured":"Nana S, Govender M, Choonara YE. Modified-release pulmonary delivery systems for labile bioactives: design, development, and applications. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/pharmaceutics17040470.","journal-title":"Pharmaceutics"},{"key":"387_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12951-022-01307-x","volume":"20","author":"S He","year":"2022","unstructured":"He S, Gui J, Xiong K, et al. A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases. J Nanobiotechnol. 2022;20:101. https:\/\/doi.org\/10.1186\/s12951-022-01307-x.","journal-title":"J Nanobiotechnol"},{"key":"387_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.63785\/cpr.2025.1.1.3044","volume":"1","author":"T Ali","year":"2025","unstructured":"Ali T. Nanomedicine approaches to overcome barriers in pulmonary drug delivery for respiratory diseases. Curr Pharm Res. 2025;1:30\u201344. https:\/\/doi.org\/10.63785\/cpr.2025.1.1.3044.","journal-title":"Curr Pharm Res"},{"key":"387_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092179","volume":"10","author":"EWX Leong","year":"2022","unstructured":"Leong EWX, Ge R. Lipid nanoparticles as delivery vehicles for inhaled therapeutics. Biomedicines. 2022;10:2179.","journal-title":"Biomedicines"},{"key":"387_CR30","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1183\/09031936.00212813","volume":"44","author":"SH van Rijt","year":"2014","unstructured":"van Rijt SH, Bein T, Meiners S. Medical nanoparticles for next generation drug delivery to the lungs. Eur Respir J. 2014;44:765\u201374. https:\/\/doi.org\/10.1183\/09031936.00212813.","journal-title":"Eur Respir J"},{"key":"387_CR31","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejps.2017.05.007","volume":"110","author":"AG Ogienko","year":"2017","unstructured":"Ogienko AG, Bogdanova EG, Trofimov NA, et al. Large porous particles for respiratory drug delivery. Glycine-based formulations. Eur J Pharm Sci. 2017;110:148\u201356. https:\/\/doi.org\/10.1016\/j.ejps.2017.05.007.","journal-title":"Eur J Pharm Sci"},{"key":"387_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4103\/0975-7406.130965","volume":"6","author":"K Madaan","year":"2014","unstructured":"Madaan K, Kumar S, Poonia N, et al. Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci. 2014;6:139\u201350. https:\/\/doi.org\/10.4103\/0975-7406.130965.","journal-title":"J Pharm Bioallied Sci"},{"key":"387_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.52711\/2231-5691.2025.00025","volume":"15","author":"MR Bachhav","year":"2025","unstructured":"Bachhav MR, Deore R, Bachhav MP, et al. Biodegradable polymers in drug delivery: a detailed review. Asian J Pharm Res. 2025;15:153. https:\/\/doi.org\/10.52711\/2231-5691.2025.00025.","journal-title":"Asian J Pharm Res"},{"key":"387_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.5681\/apb.2012.028","volume":"2","author":"Y Rahimpour","year":"2012","unstructured":"Rahimpour Y, Hamishehkar H. Lactose engineering for better performance in dry powder inhalers. Adv Pharm Bull. 2012;2:183\u20137. https:\/\/doi.org\/10.5681\/apb.2012.028.","journal-title":"Adv Pharm Bull"},{"key":"387_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15122706","volume":"15","author":"A Negi","year":"2023","unstructured":"Negi A, Nimbkar S, Moses JA. Engineering inhalable therapeutic particles: conventional and emerging approaches. Pharmaceutics. 2023;15:2706.","journal-title":"Pharmaceutics"},{"key":"387_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-1-4419-9745-6_13","volume-title":"Controlled Pulmonary Drug Delivery","author":"N El-Gendy","year":"2011","unstructured":"El-Gendy N, Bailey MM, Berkland C. Particle engineering technologies for pulmonary drug delivery. In: Smyth HDC, Hickey AJ, editors. Controlled Pulmonary Drug Delivery. New York: Springer; 2011. p. 283\u2013312."},{"key":"387_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejps.2004.02.001","volume":"22","author":"M Rehman","year":"2004","unstructured":"Rehman M, Shekunov BY, York P, et al. Optimisation of powders for pulmonary delivery using supercritical fluid technology. Eur J Pharm Sci. 2004;22:1\u201317. https:\/\/doi.org\/10.1016\/j.ejps.2004.02.001.","journal-title":"Eur J Pharm Sci"},{"key":"387_CR38","first-page":"e733","volume":"11","author":"K Srinu","year":"2024","unstructured":"Srinu K, Srinu K. Innovations in pulmonary drug delivery: a comprehensive guide to inhalation devices. J Emerg Technol Innov Res. 2024;11:e733\u201342.","journal-title":"J Emerg Technol Innov Res."},{"key":"387_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.100966","volume":"25","author":"B Wang","year":"2024","unstructured":"Wang B, Wang L, Yang Q, et al. Pulmonary inhalation for disease treatment: basic research and clinical translations. Mater Today Bio. 2024;25:100966. https:\/\/doi.org\/10.1016\/j.mtbio.2024.100966.","journal-title":"Mater Today Bio"},{"key":"387_CR40","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1513\/AnnalsATS.202202-131VP","volume":"19","author":"AS Rabin","year":"2022","unstructured":"Rabin AS, Harlan EA, Ambinder AJ. Small devices, big problems: addressing the global warming potential of metered-dose inhalers. Ann Am Thorac Soc. 2022;19:1090\u20132. https:\/\/doi.org\/10.1513\/AnnalsATS.202202-131VP.","journal-title":"Ann Am Thorac Soc"},{"key":"387_CR41","doi-asserted-by":"publisher","DOI":"10.64898\/2026.05.12.724523","author":"K Lachacz","year":"2026","unstructured":"Lachacz K, Kaye R, Mello L, et al. Pharmaceutical assessment of low global warming potential alternatives to HFA-134a in a budesonide, glycopyrrolate, and formoterol fumarate pressurized metered dose inhaler. bioRxiv. 2026. https:\/\/doi.org\/10.64898\/2026.05.12.724523.","journal-title":"bioRxiv"},{"key":"387_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.powtec.2022.117151","volume":"399","author":"YL de Charras","year":"2022","unstructured":"de Charras YL, Ram\u00edrez-Rigo MV, Bertin DE. Prediction of the particle size distribution of the aerosol generated by a pressurized metered-dose inhaler. Powder Technol. 2022;399:117151. https:\/\/doi.org\/10.1016\/j.powtec.2022.117151.","journal-title":"Powder Technol"},{"key":"387_CR43","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1208\/s12249-013-0063-x","volume":"15","author":"PB Myrdal","year":"2014","unstructured":"Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech. 2014;15:434\u201355. https:\/\/doi.org\/10.1208\/s12249-013-0063-x.","journal-title":"AAPS PharmSciTech"},{"key":"387_CR44","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1089\/jamp.2023.29104.ajh","volume":"36","author":"AJ Hickey","year":"2023","unstructured":"Hickey AJ. Dry powder inhalers: an overview. J Aerosol Med Pulm Drug Deliv. 2023;36:316\u201323. https:\/\/doi.org\/10.1089\/jamp.2023.29104.ajh.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"387_CR45","doi-asserted-by":"publisher","first-page":"2003921","DOI":"10.1183\/13993003.03921-2020","volume":"57","author":"RA Pleasants","year":"2021","unstructured":"Pleasants RA, Tilley SL, Hickey AJ, Usmani OS. User-life of ICS\/LABA inhaler devices should be considered when prescribed as relievers. Eur Respir J. 2021;57:2003921. https:\/\/doi.org\/10.1183\/13993003.03921-2020.","journal-title":"Eur Respir J"},{"key":"387_CR46","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1089\/jamp.2024.29110.jbf","volume":"37","author":"JB Fink","year":"2024","unstructured":"Fink JB, Stapleton KW. Nebulizers. J Aerosol Med Pulm Drug Deliv. 2024;37:140\u201356. https:\/\/doi.org\/10.1089\/jamp.2024.29110.jbf.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"387_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/atmos14101509","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Chen X, Li Z, et al. Optimization of vibrating mesh nebulizer air inlet structure for pulmonary drug delivery. Atmosphere (Basel). 2023;14:1509.","journal-title":"Atmosphere (Basel)"},{"key":"387_CR48","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1248\/cpb.c25-00532","volume":"74","author":"M Ikeda-Imafuku","year":"2026","unstructured":"Ikeda-Imafuku M, Fukuda H, Fukuta T, Kadota K. Advancements in inhalation technologies for pulmonary delivery of protein therapeutics. Chem Pharm Bull (Tokyo). 2026;74:28\u201336. https:\/\/doi.org\/10.1248\/cpb.c25-00532.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"387_CR49","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.2174\/1389201021666201126144057","volume":"27","author":"Y Liang","year":"2021","unstructured":"Liang Y, Mak JCW. Inhaled therapies for asthma and chronic obstructive pulmonary disease. Curr Pharm Des. 2021;27:1469\u201381. https:\/\/doi.org\/10.2174\/1389201021666201126144057.","journal-title":"Curr Pharm Des"},{"key":"387_CR50","first-page":"273","volume-title":"Advances in Pharmacology","author":"MYT Chow","year":"2023","unstructured":"Chow MYT, Pan HW, Lam JKW. Chapter ten\u2014Delivery technology of inhaled therapy for asthma and COPD. In: Wong WSF, editor. Advances in Pharmacology. Academic Press; 2023. p. 273\u2013311."},{"key":"387_CR51","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jcf.2019.08.001","volume":"19","author":"D Bilton","year":"2020","unstructured":"Bilton D, Pressler T, Fajac I, et al. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Cyst Fibros. 2020;19:284\u201391. https:\/\/doi.org\/10.1016\/j.jcf.2019.08.001.","journal-title":"J Cyst Fibros"},{"key":"387_CR52","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1080\/14656566.2018.1524873","volume":"19","author":"F Granella","year":"2018","unstructured":"Granella F. Inhaled migraine drug therapy: a start of the art therapeutic strategy or just another gimmick? Expert Opin Pharmacother. 2018;19:1743\u20135. https:\/\/doi.org\/10.1080\/14656566.2018.1524873.","journal-title":"Expert Opin Pharmacother"},{"key":"387_CR53","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s10741-025-10527-w","volume":"30","author":"A Alogna","year":"2025","unstructured":"Alogna A, Lo Muzio FP, Catalucci D. Cardiovascular inhalation for targeted drug delivery in cardiac disease. Heart Fail Rev. 2025;30:1103\u201311. https:\/\/doi.org\/10.1007\/s10741-025-10527-w.","journal-title":"Heart Fail Rev"},{"key":"387_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2025.100666","volume":"25","author":"A Bandell","year":"2025","unstructured":"Bandell A, Kassianos G, Dibben O, El Azzi G. Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019\u20132023). Vaccine X. 2025;25:100666. https:\/\/doi.org\/10.1016\/j.jvacx.2025.100666.","journal-title":"Vaccine X"},{"key":"387_CR55","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.5856","volume":"157","author":"K Ghadimi","year":"2022","unstructured":"Ghadimi K, Cappiello J, Cooter-Wright M, et al. Inhaled pulmonary vasodilator therapy in adult lung transplant: a randomized clinical trial. JAMA Surg. 2022;157:e215856. https:\/\/doi.org\/10.1001\/jamasurg.2021.5856.","journal-title":"JAMA Surg"},{"key":"387_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020564","author":"M Benedetto","year":"2024","unstructured":"Benedetto M, Piccone G, Gottin L, et al. Inhaled pulmonary vasodilators for the treatment of right ventricular failure in cardio-thoracic surgery: is one better than the others? J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13020564.","journal-title":"J Clin Med"},{"issue":"18","key":"387_CR57","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2026.41.e81","volume":"41","author":"G-Y Song","year":"2026","unstructured":"Song G-Y, Ahn S-Y, Jang HC, et al. Aerosolized pentamidine is an effective prophylaxis for pneumocystis jiroveci pneumonia in adults undergoing allogeneic hematopoietic cell transplantation. J Korean Med Sci. 2026;41(18):e81.","journal-title":"J Korean Med Sci."},{"key":"387_CR58","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ejps.2019.04.001","volume":"133","author":"R Teymouri Rad","year":"2019","unstructured":"Teymouri Rad R, Dadashzadeh S, Vatanara A, et al. Tadalafil nanocomposites as a dry powder formulation for inhalation, a new strategy for pulmonary arterial hypertension treatment. Eur J Pharm Sci. 2019;133:275\u201386. https:\/\/doi.org\/10.1016\/j.ejps.2019.04.001.","journal-title":"Eur J Pharm Sci"},{"key":"387_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14050895","author":"S Zendehdel Baher","year":"2022","unstructured":"Zendehdel Baher S, Yaqoubi S, Asare-Addo K, et al. Dry powder formulation of simvastatin nanoparticles for potential application in pulmonary arterial hypertension. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14050895.","journal-title":"Pharmaceutics"},{"key":"387_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17020224","author":"JS Park","year":"2025","unstructured":"Park JS, Choi YH, Min JY, et al. Fundamental and targeted approaches in pulmonary arterial hypertension treatment. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/pharmaceutics17020224.","journal-title":"Pharmaceutics"},{"key":"387_CR61","doi-asserted-by":"publisher","first-page":"293","DOI":"10.21037\/atm.2017.07.21","volume":"5","author":"A Artigas","year":"2017","unstructured":"Artigas A, Camprub\u00ed-Rimblas M, Tantiny\u00e0 N, et al. Inhalation therapies in acute respiratory distress syndrome. Ann Transl Med. 2017;5:293. https:\/\/doi.org\/10.21037\/atm.2017.07.21.","journal-title":"Ann Transl Med"},{"key":"387_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/biom14080904","volume":"14","author":"Y Huang","year":"2024","unstructured":"Huang Y, Zhang J, Wang X, et al. Aerosol inhalation of gene delivery therapy for pulmonary diseases. Biomolecules. 2024;14:904.","journal-title":"Biomolecules"},{"key":"387_CR63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.arbres.2021.03.009","volume":"58","author":"D De la Rosa Carrillo","year":"2022","unstructured":"De la Rosa Carrillo D, Mart\u00ednez-Garc\u00eda M\u00c1, Barreiro E, et al. Effectiveness and safety of inhaled antibiotics in patients with chronic obstructive pulmonary disease. A multicentre observational study. Arch Bronconeumol. 2022;58:11\u201321. https:\/\/doi.org\/10.1016\/j.arbres.2021.03.009.","journal-title":"Arch Bronconeumol"},{"key":"387_CR64","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1111\/jam.15053","volume":"131","author":"Y Wang","year":"2021","unstructured":"Wang Y. Liposome as a delivery system for the treatment of biofilm-mediated infections. J Appl Microbiol. 2021;131:2626\u201339. https:\/\/doi.org\/10.1111\/jam.15053.","journal-title":"J Appl Microbiol"},{"key":"387_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107661","volume":"227","author":"N Islam","year":"2024","unstructured":"Islam N, Reid D. Inhaled antibiotics: a promising drug delivery strategies for efficient treatment of lower respiratory tract infections (LRTIs) associated with antibiotic resistant biofilm-dwelling and intracellular bacterial pathogens. Respir Med. 2024;227:107661. https:\/\/doi.org\/10.1016\/j.rmed.2024.107661.","journal-title":"Respir Med"},{"key":"387_CR66","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.jcf.2020.12.012","volume":"20","author":"F Frost","year":"2021","unstructured":"Frost F, Young GR, Wright L, et al. The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: an open-label randomised crossover study (AZTEC-CF). J Cyst Fibros. 2021;20:994\u20131002. https:\/\/doi.org\/10.1016\/j.jcf.2020.12.012.","journal-title":"J Cyst Fibros"},{"key":"387_CR67","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1248\/bpb.b16-00354","volume":"39","author":"T Srichana","year":"2016","unstructured":"Srichana T, Ratanajamit C, Juthong S, et al. Evaluation of proinflammatory cytokines and adverse events in healthy volunteers upon inhalation of antituberculosis drugs. Biol Pharm Bull. 2016;39:1815\u201322. https:\/\/doi.org\/10.1248\/bpb.b16-00354.","journal-title":"Biol Pharm Bull"},{"key":"387_CR68","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40261-021-01010-z","volume":"41","author":"SM Hoy","year":"2021","unstructured":"Hoy SM. Amikacin liposome inhalation suspension in refractory Mycobacterium avium complex lung disease: a profile of its use. Clin Drug Investig. 2021;41:405\u201312. https:\/\/doi.org\/10.1007\/s40261-021-01010-z.","journal-title":"Clin Drug Investig"},{"key":"387_CR69","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s40265-020-01307-x","volume":"80","author":"J Paik","year":"2020","unstructured":"Paik J. Levodopa inhalation powder: a review in Parkinson\u2019s disease. Drugs. 2020;80:821\u20138. https:\/\/doi.org\/10.1007\/s40265-020-01307-x.","journal-title":"Drugs"},{"key":"387_CR70","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/14622200600789916","volume":"8","author":"SI Rennard","year":"2006","unstructured":"Rennard SI, Glover ED, Leischow S, et al. Efficacy of the nicotine inhaler in smoking reduction: a double-blind, randomized trial. Nicotine Tob Res. 2006;8:555\u201364. https:\/\/doi.org\/10.1080\/14622200600789916.","journal-title":"Nicotine Tob Res"},{"key":"387_CR71","doi-asserted-by":"publisher","DOI":"10.1093\/BIB\/BBAG311","author":"MJ Mathew","year":"2026","unstructured":"Mathew MJ, Mathew J, Chacko RM, et al. Decoding disease and therapy through multiomics integration and systems analysis. Brief Bioinform. 2026. https:\/\/doi.org\/10.1093\/BIB\/BBAG311.","journal-title":"Brief Bioinform"},{"key":"387_CR72","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/14622416.2025.2591596","volume":"26","author":"AL Jakka","year":"2025","unstructured":"Jakka AL, Chacko RM, Vasam M, et al. From genomics to clinic: the transformative impact of AI in pharmacogenomics and personalized medicine. Pharmacogenomics. 2025;26:573\u201385. https:\/\/doi.org\/10.1080\/14622416.2025.2591596.","journal-title":"Pharmacogenomics"},{"key":"387_CR73","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/CELLS11050801\/S1","volume":"11","author":"SR Bonam","year":"2022","unstructured":"Bonam SR, Chauvin C, Mathew MJ, Bayry J. IFN-\u03b3 induces PD-L1 expression in primed human basophils. Cells. 2022;11:801. https:\/\/doi.org\/10.3390\/CELLS11050801\/S1.","journal-title":"Cells"},{"key":"387_CR74","doi-asserted-by":"publisher","first-page":"1753478","DOI":"10.3389\/FIMMU.2026.1753478\/TEXT","volume":"17","author":"SC Singh","year":"2026","unstructured":"Singh SC, Retnakumar SV, Das M, et al. Intravenous immunoglobulin remodels innate immune cell communication and induces differential autophagy pathways in Kawasaki disease. Front Immunol. 2026;17:1753478. https:\/\/doi.org\/10.3389\/FIMMU.2026.1753478\/TEXT.","journal-title":"Front Immunol"},{"key":"387_CR75","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3390\/VACCINES12050543\/S1","volume":"12","author":"SR Bonam","year":"2024","unstructured":"Bonam SR, Hazell NC, Mathew MJ, et al. Innate and adaptive immune parameters following mRNA vaccination in mice. Vaccines (Basel). 2024;12:543. https:\/\/doi.org\/10.3390\/VACCINES12050543\/S1.","journal-title":"Vaccines (Basel)"},{"key":"387_CR76","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ebiom.2018.07.035","volume":"35","author":"G Burgess","year":"2018","unstructured":"Burgess G, Boyce M, Jones M, et al. Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942. EBioMedicine. 2018;35:67\u201375. https:\/\/doi.org\/10.1016\/j.ebiom.2018.07.035.","journal-title":"EBioMedicine"},{"key":"387_CR77","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1007\/s13346-025-01909-6","volume":"15","author":"NA Shaibie","year":"2025","unstructured":"Shaibie NA, Mohammad Faizal NDF, Buang F, et al. Inhaled biologics for respiratory diseases: clinical potential and emerging technologies. Drug Deliv Transl Res. 2025;15:4098\u2013114. https:\/\/doi.org\/10.1007\/s13346-025-01909-6.","journal-title":"Drug Deliv Transl Res"},{"key":"387_CR78","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12016-025-09045-2","volume":"68","author":"L Sahnoon","year":"2025","unstructured":"Sahnoon L, Bajbouj K, Mahboub B, et al. Targeting IL-13 and IL-4 in asthma: therapeutic implications on airway remodeling in severe asthma. Clin Rev Allergy Immunol. 2025;68:44. https:\/\/doi.org\/10.1007\/s12016-025-09045-2.","journal-title":"Clin Rev Allergy Immunol"},{"key":"387_CR79","doi-asserted-by":"publisher","first-page":"e20220270","DOI":"10.36416\/1806-3756\/e20220270","volume":"48","author":"M Urrutia-Pereira","year":"2023","unstructured":"Urrutia-Pereira M, Chong-Neto HJ, Winders TA, Sol\u00e9 D. Environmental impact of inhaler devices on respiratory care: a narrative review. J Bras Pneumol. 2023;48:e20220270. https:\/\/doi.org\/10.36416\/1806-3756\/e20220270.","journal-title":"J Bras Pneumol"},{"key":"387_CR80","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4103\/atm.atm_192_23","volume":"19","author":"S Al-Anazi","year":"2024","unstructured":"Al-Anazi S, Al-Omari A, Alanazi S, et al. Artificial intelligence in respiratory care: current scenario and future perspective. Ann Thorac Med. 2024;19:117\u201330. https:\/\/doi.org\/10.4103\/atm.atm_192_23.","journal-title":"Ann Thorac Med"},{"key":"387_CR81","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40199-021-00423-7","volume":"30","author":"J Rebello","year":"2022","unstructured":"Rebello J, Brashier B, Shukla S. Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: a systematic review. Daru J Pharm Sci. 2022;30:229\u201343. https:\/\/doi.org\/10.1007\/s40199-021-00423-7.","journal-title":"Daru J Pharm Sci"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00387-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-026-00387-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00387-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:02:42Z","timestamp":1791252162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-026-00387-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":81,"alternative-id":["387"],"URL":"https:\/\/doi.org\/10.1007\/s41030-026-00387-6","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"25 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dil Afrose, Melika Valizadeh, Shailesh B. Kolekar, Mano J. Mathew, Alexandr Ceasovschih, Alexandru Corlateanu\u00a0and Pradeesh Sivapalan have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}